{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-008123","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.408937+00:00","generated_at":"2026-06-06T16:09:58.795294+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"enGene reports FY2023 net loss $104.7M; Phase 1 LEGEND study 68% CR rate, interim data mid-2024","bullets":["FY2023 net loss $104.7M ($151.22/share) vs $29.0M ($44.30) in FY2022; operating expenses $26.0M.","Phase 1 LEGEND study in BCG-unresponsive NMIBC met endpoints; 68% complete response at 3 months (n=22); pivotal Phase 2 enrolling, interim data mid-2024.","Completed reverse merger with FEAC and upsized PIPE financing, net proceeds ~$109M; launched on Nasdaq Nov 1, 2023.","Expanded Hercules debt facility to $50M ($22.5M funded); cash $81.5M at Oct 31, 2023, runway into Q2 2025.","Leadership hires: Alex Nichols (President/COO), Richard Bryce (CMO), Ryan Daws (CFO), Lota Zoth (Board)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-008123","json":"https://secwatch.observer/filing/0000950170-24-008123.json","markdown":"https://secwatch.observer/filing/0000950170-24-008123.md","text":"https://secwatch.observer/filing/0000950170-24-008123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/0000950170-24-008123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/engn-20240129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T16:09:58.795294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72c4ef10e90e88579231b7b16bf09832faa6ebb2","claim":"enGene Therapeutics Inc. reported the fiscal year ended October 31, 2023 results: net income $104.7 million, EPS $151.22 per share.","evidence_excerpt":"For the full year 2023, net loss attributable to common shareholders was $104.7 million, or $151.22 per share, compared to $29.0 million, or $44.30 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024008123/0000950170-24-008123-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended October 31, 2023"},{"label":"Net income","value":"$104.7 million"},{"label":"EPS","value":"$151.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}